Glycopyrronium bromide (NVA237) is a novel, oncedaily
LAMA under development for the treatment of COPD.
Preliminary studies in patients with moderate to severe COPD
have shown that once-daily NVA237 provides sustained
24-hour bronchodilation, has, like short-acting bronchodilators,
a rapid onset of action, and is well-tolerated, with a
good safety profile.15,17,18 Results from the recently completed
GLOW1 trial, a Phase III, randomized, placebo-controlled
study lasting 26 weeks, support the findings of preliminary
studies and confirm the efficacy and safety of NVA237 50 μg
in patients with moderate to severe COPD.19
The principal objective of the Phase III GLycopyrronium
bromide in COPD airWays clinical study 3 (GLOW3) was to
evaluate the effect of once-daily NVA237 50 μg on exercise
tolerance in patients with moderate to severe COPD.
Glycopyrronium bromide (NVA237) is a novel, oncedailyLAMA under development for the treatment of COPD.Preliminary studies in patients with moderate to severe COPDhave shown that once-daily NVA237 provides sustained24-hour bronchodilation, has, like short-acting bronchodilators,a rapid onset of action, and is well-tolerated, with agood safety profile.15,17,18 Results from the recently completedGLOW1 trial, a Phase III, randomized, placebo-controlledstudy lasting 26 weeks, support the findings of preliminarystudies and confirm the efficacy and safety of NVA237 50 μgin patients with moderate to severe COPD.19The principal objective of the Phase III GLycopyrroniumbromide in COPD airWays clinical study 3 (GLOW3) was toevaluate the effect of once-daily NVA237 50 μg on exercisetolerance in patients with moderate to severe COPD.
การแปล กรุณารอสักครู่..
![](//thimg.ilovetranslation.com/pic/loading_3.gif?v=b9814dd30c1d7c59_8619)